HOME >> BIOLOGY >> NEWS
Wistar-developed antibody shows promise against brain tumors in Drexel trial

PHILADELPHIA - A new treatment procedure for high-grade cancers of the brain, one of the most aggressive and deadliest forms of cancer, has shown promise in extending the survival time of patients participating in a clinical trial conducted under the supervision of Luther W. Brady, M.D., the Hylda Cohn/American Cancer Society Professor of Clinical Oncology at Drexel University College of Medicine. The trial was performed in collaboration with The Wistar Institute in Philadelphia.

The findings, published in the December issue of the American Journal of Clinical Oncology, are the results of the first 10 years of an ongoing study begun in 1987. The study follows 180 patients who, following surgery and radiation therapy for their brain tumors, received injections of MAb425, a radioiodinated monoclonal antibody developed at The Wistar Institute. All of the patients were followed for five years or longer.

"These results clearly indicate a dramatic step forward in the treatment of brain tumors," says Brady.

Typically, patients with lower-grade gliomas, or brain tumors, die within 18 to 24 months, according to Brady. Patients with glioblastomas, a more aggressive form of tumor, usually die within 12 to 18 months. Of the 180 patients receiving the MAb425 injections, three patients with high-grade tumors were alive after five years and longer. Of the patients with the less aggressive tumor, eight were alive after five years and longer, and 50 percent of those patients were alive after 56 months.

"It's gratifying to see an antibody discovered in a Wistar laboratory showing such promise in the clinic against difficult-to-treat brain tumors," says Russel E. Kaufman, M.D., director and CEO of The Wistar Institute. "The process of translating basic discoveries into new therapies is often a lengthy and challenging one, but the reward can be profound - the ability to offer longer, healthier lives to patients."

The scientists who develo
'"/>

Contact: Franklin Hoke
hoke@wistar.upenn.edu
215-898-3716
The Wistar Institute
16-Dec-2002


Page: 1 2

Related biology news :

1. Wistar-discovered antibody will help diagnose appendicitis
2. Experimental hantavirus vaccine elicits strong antibody response in primates
3. Towards an AIDS vaccine: unusual antibody that targets HIV described by scientists at TSRI
4. Structure of HIV-neutralizing antibody solved
5. New antibody library speeds search for new detection tools
6. FDA approves new treatment, Campath , humanized monoclonal antibody, for patients with B-cell chronic lymphocytic leukemia
7. Rockefeller University researchers discover immune-cell mechanism that boosts therapeutic antibody potency
8. Abgenix to become sole owner of Xenomouse fully human antibody technology
9. Abgenix and CuraGen establish large-scale drug development alliance, companies to develop genomics-based human antibody drugs
10. Human Genome Sciences and Abgenix enter a broad collaboration to create fully human antibody therapeutics
11. Abgenix and Chiron enter Xenomouse Technology Collaboration, targets antibody products for autoimmune disease and cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/18/2019)... ... 2019 , ... Periodontal disease, where bacterial infection of the gums causes chronic ... population. Making this disease particularly challenging to treat is the fact that the ... in a sticky extracellular material that makes them more resistant to antibiotic treatment. ...
(Date:3/14/2019)... , ... March 14, 2019 , ... ... on Mac, Windows and mobile, today announces the launch of its North American ... volume, geographies and vertical markets, enabling them to add FileWave’s industry-leading solutions to ...
(Date:3/13/2019)... EGG HARBOR, N.J. (PRWEB) , ... March 13, 2019 , ... ... detection systems for the Pharmaceutical, Biotechnology and Medical Device Industries, is excited to announce ... changed ownership in early February 2019 and the newly installed and highly experienced ...
Breaking Biology News(10 mins):
(Date:3/12/2019)... ... March 11, 2019 , ... Centura Health, the region’s ... the first in the nation, to offer needle-free blood draws for inpatients. , ... degree to which staff showed compassion jumped up by an average of 15.4% ...
(Date:3/9/2019)... (PRWEB) , ... March 07, 2019 , ... ... is a pioneer in the development and commercialization of high performance, cutting-edge cell ... a leading European CRO with GLP-certified expertise in cardiovascular pharmacology and electrophysiology, are ...
(Date:3/4/2019)... ... ... hot topics through free webinars presented by leading experts in pharma, biotech, medical device and ... save your place! Participate in the discussion and stay relevant in your field! , Visit ... March 20 – Implementing BYOD Across Phase II and III Clinical Trials , ...
(Date:2/22/2019)... ... February 20, 2019 , ... ... emerging leader in the rapidly growing NGS (Next Generation Sequencing) field, have announced ... laboratory and incubator. , "As an innovation center and idea incubator, we are ...
Breaking Biology Technology:
Cached News: